All In Biotech

Drug Trial Radar · NCT07223047

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Oct 13, 2028

Study completion Oct 13, 2028

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

Conditions

  • Advanced Solid Malignancies
  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • BMS-986523Drug

    Specified dose on specified days

  • GemcitabineDrug

    Specified dose on specified days

  • Nab-PaclitaxelDrug

    Specified dose on specified days

  • CetuximabDrug

    Specified dose on specified days

  • PembrolizumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 3 years
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to 3 years
  3. Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteriaTime frame: Up to 3 years
  4. Number of participants with AEs leading to discontinuationTime frame: Up to 3 years
  5. Number of deathsTime frame: Up to 3 years

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • BC Cancer Vancouver

    Vancouver, British Columbia, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Local Institution - 0006

    Badalona, Barcelona [Barcelona], Spain · Not yet recruiting

  • Local Institution - 0008

    Hortaleza, Madrid, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.